These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 30429369

  • 1. Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis.
    Pender MP, Csurhes PA, Smith C, Douglas NL, Neller MA, Matthews KK, Beagley L, Rehan S, Crooks P, Hopkins TJ, Blum S, Green KA, Ioannides ZA, Swayne A, Aftab BT, Hooper KD, Burrows SR, Thompson KM, Coulthard A, Khanna R.
    JCI Insight; 2018 Nov 15; 3(22):. PubMed ID: 30429369
    [Abstract] [Full Text] [Related]

  • 2. Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis.
    Pender MP, Csurhes PA, Smith C, Beagley L, Hooper KD, Raj M, Coulthard A, Burrows SR, Khanna R.
    Mult Scler; 2014 Oct 15; 20(11):1541-4. PubMed ID: 24493474
    [Abstract] [Full Text] [Related]

  • 3. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis.
    Jilek S, Schluep M, Meylan P, Vingerhoets F, Guignard L, Monney A, Kleeberg J, Le Goff G, Pantaleo G, Du Pasquier RA.
    Brain; 2008 Jul 15; 131(Pt 7):1712-21. PubMed ID: 18550621
    [Abstract] [Full Text] [Related]

  • 4. Cumulative Roles for Epstein-Barr Virus, Human Endogenous Retroviruses, and Human Herpes Virus-6 in Driving an Inflammatory Cascade Underlying MS Pathogenesis.
    Meier UC, Cipian RC, Karimi A, Ramasamy R, Middeldorp JM.
    Front Immunol; 2021 Jul 15; 12():757302. PubMed ID: 34790199
    [Abstract] [Full Text] [Related]

  • 5. Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis.
    Pender MP, Csurhes PA, Lenarczyk A, Pfluger CM, Burrows SR.
    J Neurol Neurosurg Psychiatry; 2009 May 15; 80(5):498-505. PubMed ID: 19015225
    [Abstract] [Full Text] [Related]

  • 6. Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive Tumors.
    Eom HS, Choi BK, Lee Y, Lee H, Yun T, Kim YH, Lee JJ, Kwon BS.
    J Immunother; 2016 Apr 15; 39(3):140-8. PubMed ID: 26938947
    [Abstract] [Full Text] [Related]

  • 7. 'Off-the-shelf' allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies.
    Sinha D, Srihari S, Beckett K, Le Texier L, Solomon M, Panikkar A, Ambalathingal GR, Lekieffre L, Crooks P, Rehan S, Neller MA, Smith C, Khanna R.
    J Immunother Cancer; 2021 Feb 15; 9(2):. PubMed ID: 33589524
    [Abstract] [Full Text] [Related]

  • 8. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
    Wang Y, Aïssi-Rothe L, Virion JM, De Carvalho Bittencourt M, Ulas N, Audonnet S, Salmon A, Clement L, Venard V, Jeulin H, Stoltz JF, Decot V, Bensoussan D.
    Cytotherapy; 2014 Jan 15; 16(1):122-34. PubMed ID: 24094498
    [Abstract] [Full Text] [Related]

  • 9. Epstein-Barr Virus-Specific CD8 T Cells Selectively Infiltrate the Brain in Multiple Sclerosis and Interact Locally with Virus-Infected Cells: Clue for a Virus-Driven Immunopathological Mechanism.
    Serafini B, Rosicarelli B, Veroni C, Mazzola GA, Aloisi F.
    J Virol; 2019 Dec 15; 93(24):. PubMed ID: 31578295
    [Abstract] [Full Text] [Related]

  • 10. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
    Kalra M, Gerdemann U, Luu JD, Ngo MC, Leen AM, Louis CU, Rooney CM, Gottschalk S.
    Cytotherapy; 2019 Feb 15; 21(2):212-223. PubMed ID: 30396848
    [Abstract] [Full Text] [Related]

  • 11. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
    Nowakowska J, Stuehler C, Egli A, Battegay M, Rauser G, Bantug GR, Brander C, Hess C, Khanna N.
    Cytotherapy; 2015 Sep 15; 17(9):1280-91. PubMed ID: 26276009
    [Abstract] [Full Text] [Related]

  • 12. Sustained Clinical Improvement in a Subset of Patients With Progressive Multiple Sclerosis Treated With Epstein-Barr Virus-Specific T Cell Therapy.
    Ioannides ZA, Csurhes PA, Douglas NL, Mackenroth G, Swayne A, Thompson KM, Hopkins TJ, Green KA, Blum S, Hooper KD, Wyssusek KH, Coulthard A, Pender MP.
    Front Neurol; 2021 Sep 15; 12():652811. PubMed ID: 33790852
    [Abstract] [Full Text] [Related]

  • 13. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
    Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, Schiavo R, Secondino S, Frasson C, Perotti C, Moroni M, Locatelli F, Siena S.
    J Clin Oncol; 2005 Dec 10; 23(35):8942-9. PubMed ID: 16204009
    [Abstract] [Full Text] [Related]

  • 14. Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4+ and CD8+ T cell responses.
    Choi IK, Wang Z, Ke Q, Hong M, Qian Y, Zhao X, Liu Y, Kim HJ, Ritz J, Cantor H, Rajewsky K, Wucherpfennig KW, Zhang B.
    Proc Natl Acad Sci U S A; 2018 Jan 23; 115(4):E686-E695. PubMed ID: 29311309
    [Abstract] [Full Text] [Related]

  • 15. Epstein-Barr virus and multiple sclerosis: potential opportunities for immunotherapy.
    Pender MP, Burrows SR.
    Clin Transl Immunology; 2014 Oct 23; 3(10):e27. PubMed ID: 25505955
    [Abstract] [Full Text] [Related]

  • 16. No evidence for intrathecal IgG synthesis to Epstein Barr virus nuclear antigen-1 in multiple sclerosis.
    Jafari N, van Nierop GP, Verjans GM, Osterhaus AD, Middeldorp JM, Hintzen RQ.
    J Clin Virol; 2010 Sep 23; 49(1):26-31. PubMed ID: 20638898
    [Abstract] [Full Text] [Related]

  • 17. Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells.
    Rancan C, Schirrmann L, Hüls C, Zeidler R, Moosmann A.
    PLoS Pathog; 2015 Jun 23; 11(6):e1004906. PubMed ID: 26067064
    [Abstract] [Full Text] [Related]

  • 18. Intrathecal CD8 T-cells of multiple sclerosis patients recognize lytic Epstein-Barr virus proteins.
    van Nierop GP, Mautner J, Mitterreiter JG, Hintzen RQ, Verjans GM.
    Mult Scler; 2016 Mar 23; 22(3):279-91. PubMed ID: 26041797
    [Abstract] [Full Text] [Related]

  • 19. Decreased CD8+ T cell response to Epstein-Barr virus infected B cells in multiple sclerosis is not due to decreased HLA class I expression on B cells or monocytes.
    Pender MP, Csurhes PA, Pfluger CM, Burrows SR.
    BMC Neurol; 2011 Aug 03; 11():95. PubMed ID: 21810280
    [Abstract] [Full Text] [Related]

  • 20. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis.
    Lünemann JD, Edwards N, Muraro PA, Hayashi S, Cohen JI, Münz C, Martin R.
    Brain; 2006 Jun 03; 129(Pt 6):1493-506. PubMed ID: 16569670
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.